Skip to main
INVA

Innoviva (INVA) Stock Forecast & Price Target

Innoviva (INVA) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 20%

Bulls say

Innoviva is a company with a strong portfolio of royalty healthcare assets and a diversified business model that includes both commercialized products and strategic investments. Their stable and established target markets, along with multiple already approved and marketed products, provide for a positive outlook on the company's financial prospects. The company's recent acquisitions and partnerships, as well as their strong cash position and low debt, suggest potential for long-term growth and success in the healthcare industry.

Bears say

Innoviva is facing a modest top-line miss due to softened royalty-based revenue, leading to downgraded full-year revenue forecasts through 2027. However, the company's bottom-line results were significantly boosted by gains from its investment portfolio, indicating a lack of primary reliance on its core royalty assets. Additionally, Innoviva's reliance on its internally marketed products and strategic investments may not be sustainable or lucrative in the long term, making the stock a risky investment with limited upside potential.

Innoviva (INVA) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 20% predict a Strong Sell.

This aggregate rating is based on analysts' research of Innoviva and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Innoviva (INVA) Forecast

Analysts have given Innoviva (INVA) a Buy based on their latest research and market trends.

According to 5 analysts, Innoviva (INVA) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Innoviva (INVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.